Combination therapy for lymphoma that has returned or not responded
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called stapokibart combined with another immunotherapy to see if it can help people with lymphoma that has come back or not responded to earlier treatments. The goal is to shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of lymphoma that has returned or not improved after treatment.
- You must have previously tried an immunotherapy (like a checkpoint inhibitor) and it did not work or you could not continue it.
- You should be in generally good health (able to manage daily activities on your own).
- You need to have at least one tumor that can be measured on a scan.
- Your blood counts and organ function (liver, kidneys) must be within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of three drugs (golidocitinib, pegaspargase, and an immune checkpoint inhibitor) as the first treatment for advanced extranodal natural killer/T-cell lymphoma. The goal is to see if this combination can shrink or eliminate the cancer and improve outcomes.
This trial tests two drugs, Finotonlimab and Stapokibart, for people with head and neck cancer that has come back or spread to other parts of the body. It may help if you've already tried a PD-1 drug and platinum chemotherapy, but the cancer got worse.
This trial tests a new drug combination for people with a rare type of lymphoma (ENKTL) that has come back or not responded after prior treatment. It aims to see if the combination can help control the disease.
This trial tests a combination of two medicines for people with non-small cell lung cancer that has worsened after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.